|
Volumn 18, Issue 16, 2010, Pages 5775-5794
|
Process R&D under the magnifying glass: Organization, business model, challenges, and scientific context
|
Author keywords
Organic synthesis; Pharmaceuticals; Process design; Process R D; Scale up
|
Indexed keywords
AR A2;
CHROMAN DERIVATIVE;
EBALZOTAN;
ESOMEPRAZOLE;
FLUOXETINE;
MONOCLONAL ANTIBODY;
OMEPRAZOLE;
POTASSIUM CARBONATE;
ROBALZOTAN;
ROPIVACAINE;
SEROTONIN 1B ANTAGONIST;
UNCLASSIFIED DRUG;
ZIMELDINE;
CHEMOMETRICS;
CLINICAL TRIAL;
COMMERCIAL PHENOMENA;
COMPUTER PROGRAM;
COST EFFECTIVENESS ANALYSIS;
DENSITY FUNCTIONAL THEORY;
DRUG COST;
DRUG DESIGN;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SAFETY;
DRUG SELECTIVITY;
DRUG SYNTHESIS;
ENVIRONMENTAL FACTOR;
FRIEDEL CRAFTS REACTION;
HEALTH CARE COST;
HEALTH CARE NEED;
HUMAN;
MOLECULAR WEIGHT;
ORGANIZATION;
PATENT;
PRODUCTIVITY;
QUALITY CONTROL;
REVIEW;
STEREOCHEMISTRY;
STEREOISOMERISM;
CHEMISTRY, PHARMACEUTICAL;
DRUG INDUSTRY;
RESEARCH;
|
EID: 77955471836
PISSN: 09680896
EISSN: None
Source Type: Journal
DOI: 10.1016/j.bmc.2010.06.029 Document Type: Review |
Times cited : (26)
|
References (55)
|